or a pharmaceutically acceptable salt or solvate thereof, wherein:

Q is O;

R¹ is a non-aromatic heterocyclic group selected from:

wherein R¹ is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R¹ is optionally substituted with one or more substituents independently selected from halo; —CN; —NO₂; —N₃; —R^β; —OH; —OR^β; —SH; —SR^β; —SO₂R^β; —NH₂; —NHR^β; —N(R^β)₂; —CHO; —COR^β; —COOH; —COOR^β; —OCOR^β; —R^α—CHO; —R^α—COR^β; —R^α—COOH; —R^α—COOR^β; —R^α—OCOR^β; —NH—CHO; —NR^β—CHO; —NH—COR^β; —NR^β—COR^β; —CONH₂; —CONHR^β; —CON(R^β)₂; —R^α—NH—CHO; —R^α—NR^β—CHO; —R^α—NH—COR^β; —R^α—NR^β—COR^β; —R^α—CONH₂; —R^α—CONHR^β; —R^α—CON(R^β)₂; a C₃-C₇ cycloalkyl group optionally substituted with one or more C₁-C₃ alkyl or C₁-C₃ haloalkyl groups; a C₃-C₇ cycloalkenyl group optionally substituted with one or more C₁-C₃ alkyl or C₁-C₃ haloalkyl groups;

each —R^α— is independently selected from an alkylene, alkenylene or alkynylene group, wherein the alkylene, alkenylene or alkynylene group contains from 1 to 6 carbon atoms in its backbone, and wherein the alkylene, alkenylene or alkynylene group is optionally substituted with one or more halo and/or —R^β groups;

each —R^β is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and wherein any —R^β is optionally substituted with one or more C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₃ alkyl), halo, —CN, —C≡CH or oxo (═O) groups;

each —R^β is independently selected from a C₁-C₆ alkyl or C₁-C₃ haloalkyl group;

each m is independently selected from 1, 2 or 3;

each n is independently selected from 1, 2 or 3; and

R² is: